Cardiorenalmetabolic

Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in the V-MONO study.

Research at the European Society of Cardiology Congress 2024 evaluated lipid-lowering therapy beyond statins alone in patients with high levels of low-density lipoprotein cholesterol.

Regardless of duration of type 2 diabetes, sodium-glucose cotransporter inhibitors prevented cardiovascular events, according to research presented at the European Society of Cardiology Congress 2024.

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections.

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes.

New research indicates that the heart benefits of semaglutide can extend to those with heart failure.

Heart failure mortality rates after hospital discharge have seen little improvement since 2010 among Medicare beneficiaries, with real-world outcomes falling short of clinical trial expectations.

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach.

Despite guidelines recommending annual screenings, nearly half of patients with diabetes miss critical eye exams, explains Jose A. Martinez, MD, president and retina specialist at Austin Retina Associates.

A new study found that older patients with atrial functional mitral regurgitation who underwent mitral valve surgery had significantly better outcomes than those who received medical management alone, including lower rates of heart failure hospitalization and death.

The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still struggling to meet their goals.

Martha Gulati, MD, MS, discusses the accomplishments of the American Society of Preventive Cardiology (ASPC) during her presidency and emphasizes the importance of advancing preventive cardiology.

In advance of this year’s American Society for Preventive Cardiology (ASPC) 2024 Congress on CVD Prevention, we spoke with ASPC President-Elect Michael Shapiro, DO, FASPC, about the many can't-miss sessions at this year's record-breaking event.

Researchers identify potential reductions in statin and antihypertensive therapy eligibility using Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations.

Patients with atrial fibrillation who use wearable devices, like Apple Watches and FitBits, report higher anxiety levels and increased health care usage than nonusers.

The catheter-delivered implant uses the right ventricle to support the left, improving left ventricle ejection fraction and helping restore the heart’s normal shape.

A new study revealed longer heart failure hospital stays, better 30-day follow-up, and lower mortality rates in Japan compared with the US.

Older adults with the most irregular sleep durations demonstrated a 34% higher risk of developing type 2 diabetes compared with those with the most regular sleep.

No significant differences in efficacy or safety of 2 aspirin doses were found between male and female patients for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

New studies say restricting salt intake can reduce the risk of atrial fibrillation (AF) in certain patients, but cannot reduce the risks of morbidity and death in patients with heart failure.

Up to one-third of Americans have been affected by data stolen through the Change Healthcare cyberattack; research highlights potential cognitive and psychiatric benefits of semaglutide; over 40 Iowa hospitals have ended their labor and delivery services.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, emphasizes the importance of bringing heart health care to patients and meeting them where they are.

Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did.

A new study highlights the potential of technology to aid in type 1 diabetes (T1D) management by balancing minimal user input with significant data output to improve user engagement and time in range.

The University Hospitals CINEMA program aims to address issues and narrow gaps in obesity management, with a focus on meeting patients where they are and providing them tools for success, says Ian Neeland, MD.

Robert Lustig, MD, MSL, explains how the US health care industry needs to shift from measuring body mass index and obesity to measuring cardiometabolic health, which affects 93% of Americans, including children.

Taking falsified semaglutide (Ozempic; Novo Nordisk) can lead to ineffective treatment due to incorrect dosing, contamination, and the use of unknown ingredients, the World Health Organization (WHO) is warning.

A new prevalence study shows more people are living beyond age 65 with type 1 diabetes (T1D).

Patients with diabetes who have private insurance are more likely to be prescribed a continuous glucose monitor (CGM) compared with those with government insurance, says Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center.

Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.